Guardant Health jumps 25% in a week as Medicare test looms
Guardant Health shares closed at $118.95 Friday, up 25% for the week, after the FDA approved an expanded version of its Guardant360 Liquid CDx blood test. The stock surged 17.1% on May 20 following the approval. Nasdaq will remain closed through Memorial Day, with trading set to resume Tuesday. Guardant raised its 2026 revenue outlook to $1.30–$1.32 billion after reporting a 48% jump in first-quarter revenue.
